U.S. government threatens to bar Forest CEO

Friday, April 15, 2011 12:27 PM

U.S. officials have sent a letter to Forest Laboratories chief executive Howard Solomon threatening him with a ban from participating in Medicare and Medicaid, according to Pharma Times.

Solomon, who is also Forest's chairman and president, will challenge any action by the Office of the Inspector General, Department of Health and Human Services (HHS-OIG) that would potentially exclude him from participation in federal healthcare programs. The letter from HHS-OIG relates to a settlement from September 2010 which noted the company’s guilty plea to claims of illegal marketing of the antidepressants Celexa (citalopram) and Lexapro (escitalopram) and an unapproved formulation of the thyroid treatment Levothroid (levothyroxine).

As a result Forest paid $313 million plus interest following the incident.  It also signed a corporate integrity agreement (CIA) with HHS-OIG which has now given Solomon 30 days to say why he should not be excluded.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs